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Abstract We have identified a marked over-representation of transcription factors controlling
differentiation of T, B,myeloid and NK cells among the 110MS genes now known to be associatedwith
multiple sclerosis (MS). To test if the expression of these genesmight definemolecular subtypes of MS,
we interrogated their expression in blood in three independent cohorts of untreated MS (from Sydney
and Adelaide) or clinically isolated syndrome (CIS, from San Francisco) patients. Expression of the
transcription factors (TF) controlling T and NK cell differentiation, EOMES, TBX21 and other TFs was
significantly lower in MS/CIS compared to healthy controls in all three cohorts. Expression was tightly
correlated between these TFs, with other T/NK cell TFs, and to another downregulated gene, CCL5.
Expression was stable over time, but did not predict disease phenotype. Optimal response to therapy
might be indicated by normalization of expression of these genes in blood.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.8913889.
ey.edu.au (D.R. Booth).
hed by Elsevier Inc.
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Genome wide association studies (GWAS) and the internation-
ally collaborative ImmunoChip experiment involving 10 auto-
immune diseases including Multiple Sclerosis (MS) have recently
identified hundreds of genetic variants that confer increased
risk to various autoimmune diseases. MS is a common, partially
heritable autoimmune disease, characterized by plaques of
sclerotic tissue in the central nervous system. Over 100 genetic
variants have now been identified, withmany sharedwith other
autoimmune conditions [1,2]. Genes from most of the shared
and other loci are predominantly expressed in leukocytes, and
most of the variants are in regulatory regions of the DNA [1,3],
indicating that regulation of genes in leukocytes underpins MS
susceptibility.
Transcription factors are master regulators of the tran-
scriptome, controlling lineage differentiation and cell survival.
In this study we identified an over-representation of transcrip-
tion factor genes in the recently published list of 110 non-MHC
MS susceptibility loci. Several other lines of evidence suggest
that dysregulation of gene expression in leukocytes, including in
the peripheral circulation, may drive MS. Histological studies
have shown that leukocytes from the peripheral circulation
infiltrate the central nervous system and are associated with MS
plaques [4]. Therapies designed to prevent these cells becoming
activated and crossing the blood brain barrier, have proven
highly effective in reducing relapse rates and disease burden as
indicated by the lesion load on magnetic resonance imaging
(MRI) scans in relapsing remitting MS [5–7]. Although early
effective therapeutic intervention for autoimmune diseases has
been shown to be critical in delaying progression [8], and
individuals respond to some therapies better than others,
practical biomarkers have not yet been identified to guide
clinical management.
Assessment of therapeutic success is based on prevention
of relapses and reduction of gadolinium enhanced lesions on
MRI of the brain. Relapses can be highly variable in
presentation and MRI scans are infrequently assessed, due
to cost and logistical considerations. Much neuronal damage
can precede identification of therapeutic failure, so it is
critical to identify biomarkers of therapeutic response that
can be employed to monitor disease progress more sensi-
tively and frequently [9]. Many of the GWAS genes expressed
in leukocytes are transcription factors controlling their
differentiation [1,3,10,11], implicating variation in regula-
tion of immune cell differentiation as underpinning disease
susceptibility and driving MS pathogenesis. We reasoned
that expression of these genes in blood leukocytes should
indicate disease state and type, and be useful in clinical
practice. We therefore interrogated their expression in
whole blood using RNAseq, microarray analysis and quanti-
tative RTPCR in three independent cohorts.
As a discovery cohort, we analyzed the expression of
MS-associated transcription factors in whole blood from 72
individuals (32 untreated MS, 40 controls) using RNAseq. The
transcription factors controlling T and NK cell differentiation
[12], EOMES and TBX21, were highly dysregulated in untreated
MS. We then tested this association in two independent
replication cohorts of 71 individuals from Australia (41
untreated MS, 31controls) and in 52 people from San Francisco
(15 untreated CIS/MS, 37 controls). The stability of EOMES and
TBX21 expression over time was assessed from longitudinalblood collections. The association of this expression with
disease progression, disability and clinical course was deter-
mined in each cohort. The consilience of their dysregulation,
genetic association, temporal stability, genotype-dependent
expression and the pathogenic pathways on which they
function, suggest measurement of expression levels of these
genes may be clinically useful in MS and other autoimmune
diseases.2. Material and methods
2.1. Sample collection
Single PAXgene blood RNA tubes (PreAnalytiX, Switzerland)
were collected from subjects with MS who were not
receiving any treatment, and had not received any immu-
nomodulatory therapy in the previous three months, from
clinics in Sydney, Adelaide and the University of California,
San Francisco (UCSF). Blood was also collected from healthy
controls. Each cohort was matched for age, gender and for
season, and time of day of blood draw. Demographics for
patients and controls for each cohort are shown in Table 1.
Informed written consent was obtained from each donor,
and the study was approved by the relevant Human Research
Ethics Committee.2.2. Quantitation of gene expression
mRNA from the discovery cohort was interrogated for whole
transcriptome gene expression using the Illumina Hiseq 2000
as described previously [13]. RTPCR has been used to validate
measurements in this cohort [13]. Total mRNA from the UCSF
cohort was analyzed using the Affymetrix Exon 1.0 ST array as
previously described, and Nanostring assays were used to
validate measurements in that cohort [14]. For the RT PCR
cohort cDNA was prepared from mRNA using SuperScript™ III
Reverse Transcriptase (Invitrogen, California) and Taqman
Gene Expression Assays (Life Technology, California) were
employed for the GWAS genes EOMES (Hs00172872_m1), TBX21
(Hs00203436_m1), cMAF (Hs04185012_s1), ZMIZ1 (Hs00393480_
m1), STAT3 (Hs00374280_m1); and other transcription factors
controlling T cell differentiation: RUNX3 (Hs00231709_m1), TOX
(Hs01055573_m1), ZBTB7 (Hs00757087_g1), GATA3 (Hs00231122_
m1), FOXP3 (Hs01085834_m1), RORC (Hs01076112_m1) and
GAPDH (house keeping comparator, Hs0275899_g1). Derivation
of cell subset mRNA and subsequent RNAseq has been described
previously [13].2.3. CCL5 quantitation in serum
Serum separated from whole blood was collected in a single
CAT BD Vacutainer from subjects with MS who were not
receiving any treatment, and had not received any immu-
nomodulatory therapy in the previous three months, from
clinics in Sydney, and also from healthy controls. The serum
was diluted 1/320 and quantified for CCL5 according to the
RayBio Human RANTES ELISA kit (RayBiotech Inc., Georgia).
The ELISA plate was read at 450 nm on the Victor X3
(PerkinElmer, Massachusetts) and the absorbance readings
Table 1 Demographics of Australian and American cohorts.
CIS — clinically isolated syndrome, RRMS — relapsing remitting MS, SPMS — secondary progressive MS, PPMS — primary progressive
MS, EDSS — expanded disability status scale, MSSS — Multiple Sclerosis Severity Score.
RNAseq UCSF RTPCR
HC MS HC MS HC MS
Number 40 32 38 14 30 41
Age 44.7 46.7 46.7 40.6 37 48
Age range 25–78 26–76 26–66 21–56 26–60 18–68
Gender 26F:14M 23F:9M 28F:10M 10F:4M 15F:15M 29F:12M
Summer/winter 24S:24W 16S:16W 21S:17W 5S:9W 15S:15W 22S:19W
MS
Age of onset 29.5 39.3 33.7
CIS 0 14 0
RRMS 21 0 28
SPMS 1 0 8
PPMS 10 0 5
EDSS 4.19 0 3.88
MSSS 6.96 0 4.85
18 G.P. Parnell et al.were analyzed using SoftMaxPro 4.3.1 (Molecular Devices,
California).
2.4. Statistics
The association of transcription factor (TF) expression with
disease and season was tested using an ANOVA. Age was tested
using Pearson's correlation. Two tailed T tests were then used to
assess differences in gene expression by disease state, gender
and by season. Effect of disease was determined in the RNAseq
cohort using the EdgeR Exact Test [15]. Season was defined
as “winter” months 4–9 and “summer” months 1–3, and
10–12, corresponding to the 6 months of lowest and highest
UV radiation respectively, in Sydney and Adelaide. For the
UCSF cohort these were “summer” and “winter”. Correlation
between TFs, longitudinal collections, TFs and other genes,
was determined using Pearson correlation.
3. Results
3.1. T and NK GWAS transcription factors are
underexpressed in MS
For the 110 non-HLA loci recently identified as MS-associated
[1], the closest genes to the signal for 26 of them were DNA
binding transcription factors, and 25 of these were predom-
inantly expressed in immune cells (Fig. 1A), using cell subset
transcriptomes we had derived previously from RNAseq data
[13]. In addition, TBX21 is in linkage disequilibrium (LD) with
NPEPPS as the closest gene to the most-associated SNP in
the locus. Considering that only about 300 of the 20,000
known genes are TFs expressed in immune cells [16], they
are enriched over 15 fold in the MS GWAS/ImmunoChip list
(p b 1E-05, chi-square test). We determined the relative
expression of these MS associated transcription factors using
RNAseq for 40 healthy controls and 32 MS samples (cohort
described in Table 1). In the discovery cohort, EOMES (p =
0.0002), TBX21 (p = 1.48E-06), ZMIZ1 (p = 0.0026), ZFP36L2(p = 0.0014), MAF (p = 0.0116), ZNF438 (p = 0.03), and TCF7
(p b 0.04; all p values uncorrected for multiple testing) were
differently expressed in MS. EOMES (p = 0.0060), TBX21 (p =
0.0034), ZMIZ1 (p = 0.0002) and ZFP36L2 (p = 0.0003) were
also associated with disease in the UCSF study involving 52
individuals [14], in all cases with lower expression in MS in
both cohorts (Fig. 1B).
We confirmed that these genes are predominantly expressed
in NK or T cells (EOMES, TBX21 and ZFP36L2), or myeloid cells
(ZMIZ1) (Fig. 1). We then tested expression of EOMES, TBX21
and ZMIZ1 by RTPCR with disease in a second Australian
replication cohort. Again reduced expression of these genes
was significantly associated with MS (Fig. 2, cohort details in
Table 1, association of transcription factors in Supp Table 1).
Gender and age were not associated with differences in
expression of these genes (data not shown). Time of day [17]
and season [18–20] are also known to affect immune cell subset
representation in blood. All samples were collected between
0830 and 1300; and matched for season. However, it is notable
that in one Australian cohort expression of TBX21, EOMES,
ZMIZ1 and other transcription factors were affected by season
(Supp Table 2) in healthy controls.3.2. EOMES and TBX21 expression is correlated with
each other and with expression of other NK/T cell
transcription factors
Given that EOMES and TBX21 have a similar pattern of immune
cell subset distribution (Fig. 1), we tested if their expression
was correlated with each other. Indeed, they were positively
correlated in all three cohorts (Fig. 3). Several T and NK cell
transcription factors regulating differentiation have been
characterized [21,22]. We had earlier identified that one of
the core T cell transcription factors controlling CD4/CD8
differentiation, RUNX3, was underexpressed in MS [13]. We
tested if this and other transcription factors known to regulate T
and NK cells [22] were also correlated in the three cohorts. A
set comprising EOMES, TBX21, RUNX3, and TOX (and to lesser
19G.P. Parnell et al.extent, GATA3) was highly positively correlatedwith each other
(Fig. 3, Supp Table 3; RNAseq: R ranged from 0.73 to 0.80,
p b 1E-08 for all; UCSF: R = 0.61–0.75, p b 1E-06 for all;
RTPCR: R = 0.44–0.72, p b 1E-03 for all). The GWAS TFs ZMIZ1
and ZFP36L2 were also correlated in the two cohorts tested
(RNAseq and UCSF), with highly significant p values (RNAseq:
R = 0.64, p b 2.5E-07; UCSF: R = 0.47, p b 4E-04). For Set 1
(EOMES, TBX21, RUNX3, TOX) these correlations are in
agreement with the cell subset representation of these
transcription factors (Fig. 4C), all being predominantly
expressed in T and NK cells, but transcripts from Set 2 are
only expressed in lymphocytes (ZFP36L2) and myeloid cells
(ZMIZ1) (Fig. 1A).
We had earlier identified that NK cell genes were
overrepresented in the list of genes underexpressed in MS
as compared to controls [13]. We tested if other NK cell
genes underexpressed in the MS RNAseq data were correlat-
ed with Set 1 transcription factors. Strikingly, several were,
with CCL5/EOMES being the most tightly correlated
(RNAseq: R = 0.87, p b 2.9E-17) Figs. 4A–B, Supp Table 4).
CCL5 expression was also correlated with expression of
these transcription factors in the UCSF cohort (UCSF: CCL5/
EOMES R = 0.60, p b 1.9E-06). Serum CCL5 protein was not
correlated with EOMES mRNA in whole blood in the PCR
cohort (Fig. 4D).NEURONAL T NK B MYELOID 
A
Figure 1 Expression of transcription factors associated with MS
measured by RNAseq and (B) differential expression in MS (RNASeq
independent cohorts. Orange color indicates increased expression le
RNASeq cohort is for EdgeR Exact Test [15], p value for UCSF cohort3.3. EOMES and TBX21 expression is stable
over time
The temporal stability of TBX21 and EOMES expression was
assessed in the UCSF cohort, where collections from the
same individuals from up to 3 yearly time points had been
made [14]. Expression levels from consecutive yearly time
points were highly correlated for both EOMES and TBX21 in
controls and CIS/MS (Fig. 5). The MS patients with lower
levels of expression than most controls were consistently
lower at subsequent time points. This was also true for the
other Set 1 TFs and Set 2 TFs.
This observed stable expression of the transcription factors
over time suggested expression might be under genetic control.
We sought in silico evidence that SNPs in cis and trans affect
whole blood expression of these transcription factors and CCL5.
The GWAS associated SNP for EOMES, rs11129295, is highly
associated with EOMES expression, and expression of all of the
Set 1 transcription factors (EOMES, TBX21, RUNX3, TOX), the
Set 2 transcription factor ZFP36L2, and CCL5 is genotype-
dependent (Supp Table 5, [23]). Theminor allele of rs11129295,
which is associated with increased risk of MS, is the more highly
expressed. The expression of EOMES is lower in MS, but we
would expect the expression level of EOMES in MS to be the net











1.25 0.0122 0.85 ns
ns ns
0.94 ns 0.88 0.0048
NA ns
ns ns
0.95 ns 0.87 0.0022
1.07 ns 0.85 0.0281
0.85 0.0116 0.94 ns
0.78 0.0026 0.86 0.0002
1.17 0.0395 1.00 ns
ns ns
0.96 ns 0.96 0.0346
1.01 ns 0.93 0.0379
1.07 ns 0.81 0.0002
1.03 ns 1.02 0.0129




0.94 ns 0.87 0.0462
0.67 1.48E-06 0.95 0.0034
0.73 0.0002 0.84 0.0060
ns ns
1.16 0.0424 0.83 ns
0.84 0.0014 0.96 0.0003
0.96 ns 0.93 0.0003
GENE EXPRESSION LEVEL IN WHOLE BLOOD OF
MS/CIS PATIENTS COMPARED TO HEALTHY
CONTROLS
B
by GWAS/ImmunoChip. (A) Immune cell subset expression as
) or CIS (UCSF) patients compared to healthy controls for two
vel; blue color indicates decreased expression level. p value for
is for two tailed T test.
EOMES
UCSF – p<0.0060 RTPCR – p<0.0003 RNAseq – p<0.0002
UCSF - p<0.0034  RTPCR – p<0.0073RNAseq – p<1.48E-06 
TBX21
Figure 2 Expression of transcription factors EOMES and TBX21 in whole blood of MS or CIS patients compared to healthy controls in
three independent patient cohorts. p value for RNASeq cohort is for EdgeR Exact Test [15], p value for RTPCR and UCSF cohorts is for
two tailed T test.
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and progression
We computed the association of the low expression MS
phenotype with age of onset, disability, progression and clinical
course. Disability was assessed using the expanded disability
status scale (EDSS, [24]). Progression was the rate of EDSS
change (MSSS, [25]). Clinical course was relapsing remitting MS
(RRMS), secondary progressive MS (SPMS) or primary progressive
MS (PPMS). There was no correlation between transcription
factor expression and any of these phenotypes.RNAseq Cohort
R=0.73 p <= 8.0E-10 
RTPCR Coh
R=0.75 p <=
Figure 3 Expression levels of TBX21 and EOMES are tightly correlate
(red squares for RNAseq and RTPCR cohort), and CIS (red squares for UCS
value (p).4. Discussion
The GWAS studying genetic variants affecting risk of autoim-
mune diseases have identified shared risk factors, indicating a
common molecular and cellular architecture of these diseases
[2,11]. The genetic variants mainly occur in regulatory regions,
indicating that the control of gene expression which alters
immune cell differentiation underpins variation in heritability
[26]. Here we have shown that the expression of the
transcription factors identified as MS risk genes: EOMES,
TBX21, ZFP36L2 and ZMIZ1, is low in MS. EOMES and TBX21UCSF 
R=0.66 p <= 1.2E-07
ort 
 1.8E-10  
d in three independent cohorts. Healthy controls (blue circles), MS
F cohort). R is Pearson correlation coefficient with corresponding p
RNAseq






Figure 4 Expression level of CCL5 and EOMES RNA is correlated in (A) RNAseq cohort of healthy control and MS patient samples and
(B) UCSF cohort of healthy control and CIS patient samples. R is Pearson correlation coefficient with corresponding p value (p). (C) Immune
cell subset expression of transcription factors not identified as associated with MS from GWAS. Orange color indicates increased expression
level; blue color indicates decreased expression level. (D) Correlation of serum CCL5 protein with EOMES mRNA in whole blood (RTPCR
cohort).
21G.P. Parnell et al.expression is positively correlated, as is expression of ZFP36L2
and ZMIZ1. EOMES and TBX21 expression is also positively
correlated with the T and NK cell transcription factors RUNX3,
TOX, and GATA3, and with genes under-expressed in MS,
notably CCL5. These data are replicated in three independent
cohorts. Expression of these transcription factors is stable over
time in healthy controls and CIS patients, and known to be
genotype dependent, indicating that the gene expression level
is characteristic for individuals and so defines a molecular
phenotype. The lower expression phenotype, ETlow, predicts
increased risk of MS, would be stable without intervention, but
may normalize with successful therapy. Increased expression
might be useful in assessing positive response to therapy.
The association of altered expression of transcription
factors regulating T, NK and myeloid cell subsets in all three
cohorts is consistent with other lines of evidence supporting
a role for altered immune cell differentiation in whole blood
as contributing to MS pathogenesis [27–32]. Since EOMES,
TBX21, RUNX3 and TOX are predominantly expressed in
NK and CD8CD45RO T cells, the ETlow molecular phenotype
identified here likely represents a lower contribution to the
whole blood transcriptome from these cells, or major
subsets of them. Both CD8CD45RO and NK cell subsets have
previously been reported as aberrant in MS (reviewed in[33]). Immunophenotyping with a comprehensive array of CD
markers has identified CD8lowCD4− cells, particularly NK
cells, as under-represented in peripheral blood in MS [34]. It
is notable that the genes identified as underexpressed in
whole blood in MS are predominantly from NK cells [13].
From this study we could hypothesize that those with the MS
risk phenotype also have an altered NK/CD8CD45RO cellular
phenotype. Note the stable ETlow phenotype observed
here is consistent with other studies showing stable whole
blood immunophenotype [20], chemokine and cytokine
profiles [35] and flow cytometry observations on longitudinal
variation in CD4 cell subsets [36].
The association of the ETlow phenotype with low CCL5 is
consistent with other lines of evidence suggesting that
increased immune cell trafficking from the blood contrib-
utes to, or even drives, MS pathogenesis [35,37]. The major
source of CCL5 is immune cells, so that reduced expression
of mRNA observed in MS would lead to less extracellular
CCL5 in the blood, which would lead to a chemokine gradient
out of the blood. The cells expressing receptors for CCL5
(CCR5, CCR3 and CCR1) would traffic to the tissues, and so
be more likely to promote an immune response at the target
site. Blocking this trafficking may be beneficial, especially in




Figure 5 Expression of EOMES and TBX21 is stable over time in the whole blood of healthy controls and CIS patients.
22 G.P. Parnell et al.reported as higher in the CSF of MS compared to controls
[38], an increased level of CCL5 associated with different
clinical forms of MS [39], and with lower levels of receptor in
different MS forms reported in another study [40]. Antago-
nists for CCR5 have been reported to reduce severity of EAE
[41,42]. People with HIV on long term antiretroviral therapy,
and so reduced CCR5 availability, have been reported to
have a reduced risk of MS [43]. Since these aspects of
trafficking are likely to be tissue agnostic, the ETlow
phenotype identified here may also predict risk of other
autoimmune diseases, which may respond to agents blocking
CCL5 interactions.
The transcription factors shown not to be aberrantly
expressed here, and the other MS susceptibility genes, also
regulate immune cell subset differentiation [1,10], as do
GWAS-identified genes for other autoimmune diseases [2].
Monoclonal antibodies targeting all leukocytes, or particular
subsets of leukocytes, can greatly reduce relapse rates and
numbers of gadolinium enhanced lesions detected by
MRI. These include Alemtuzumab, which targets a receptor,
CD52, expressed on all leukocytes [44]; Tysabri which
targets CD49D, expressed on T cells [6]; or Daclizumab,
which targets CD25, expressed on T and NK cells [45].
Notably CD25 (IL2Ralpha) itself, and the ligand for CD49D,
VCAM1, are in MS risk factor loci. Small molecule antagonistsfor sphingosine 1 phosphate receptors, which block traffick-
ing between the lymphoreticular system and the blood, are
also effective [46]. Many of the transcription factors
regulate B cells, and monoclonal antibodies to surface
markers specific for B cells are also effective in MS [47,48].
The cross-protection, where more than 50% of patients
respond to both B and T cell specific therapies, evident from
these studies, suggests that targeting subsets has benefits to
overall modulation of immune response. However, therapies
are not universally effective, nor without adverse reac-
tions [49], and because early control of disease is crucial in
delaying the progressive phase of the disease [8], personal-
izing therapy is crucial. The ETlow phenotype may be useful
for this purpose.
We found no association between MS clinical course or
disease severity and the ETlow phenotype, suggesting this
phenotype is unlikely to have predictive value for disease
progression in the absence of therapy. However, the many
different types of drugs now available for MS target different
immune cell subsets and processes, and may have differen-
tial effects on disease progression in individuals with
different underlying pathologies. Such differences in re-
sponse may be detectable by the extent of normalization of
the ETlow phenotype on particular therapies. Assessing this,
and identification of the immune cell subset driving this
23G.P. Parnell et al.gene expression phenotype, may lead to diagnostic tools to
choose therapy and evaluate its success, and to develop new
therapies.
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